153 related articles for article (PubMed ID: 37348162)
21. Will advanced cholangiocarcinoma become a targetable malignancy?
Sarkis Y; Al Soueidy A; Kourie HR
Crit Rev Oncol Hematol; 2021 Mar; 159():103233. PubMed ID: 33482346
[TBL] [Abstract][Full Text] [Related]
22. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
[TBL] [Abstract][Full Text] [Related]
23. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
[TBL] [Abstract][Full Text] [Related]
24. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
25. Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs.
Stutes M; Tran S; DeMorrow S
World J Gastroenterol; 2007 Dec; 13(48):6465-9. PubMed ID: 18161915
[TBL] [Abstract][Full Text] [Related]
26. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
[TBL] [Abstract][Full Text] [Related]
27. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.
Rhee H; Kim MJ; Park YN; An C
Eur Radiol; 2019 Jun; 29(6):3111-3121. PubMed ID: 30560357
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
[TBL] [Abstract][Full Text] [Related]
29. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
[TBL] [Abstract][Full Text] [Related]
30. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma.
Andresen K; Boberg KM; Vedeld HM; Honne H; Hektoen M; Wadsworth CA; Clausen OP; Karlsen TH; Foss A; Mathisen O; Schrumpf E; Lothe RA; Lind GE
Epigenetics; 2012 Nov; 7(11):1249-57. PubMed ID: 22983262
[TBL] [Abstract][Full Text] [Related]
31. Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.
Qiu Z; Ji J; Xu Y; Zhu Y; Gao C; Wang G; Li C; Zhang Y; Zhao J; Wang C; Wen X; Zhang Z; Li B; Zhang Z; Cai S; Li B; Jiang X
BMC Med; 2022 Feb; 20(1):64. PubMed ID: 35130881
[TBL] [Abstract][Full Text] [Related]
32. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
Nguyen Canh H; Takahashi K; Yamamura M; Li Z; Sato Y; Yoshimura K; Kozaka K; Tanaka M; Nakanuma Y; Harada K
Histopathology; 2021 Nov; 79(5):731-750. PubMed ID: 34018212
[TBL] [Abstract][Full Text] [Related]
33. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
34. The pathways of genetic transformation in cholangiocarcinogenesis.
Serafini FM; Radvinsky D
Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
[TBL] [Abstract][Full Text] [Related]
35. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
Yu J; Refsum E; Helsingen LM; Folseraas T; Ploner A; Wieszczy P; Barua I; Jodal HC; Melum E; Løberg M; Blom J; Bretthauer M; Adami HO; Kalager M; Ye W
United European Gastroenterol J; 2022 Mar; 10(2):212-224. PubMed ID: 35107865
[TBL] [Abstract][Full Text] [Related]
36. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
37. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data.
Bagante F; Spolverato G; Ruzzenente A; Luchini C; Tsilimigras DI; Campagnaro T; Conci S; Corbo V; Scarpa A; Guglielmi A; Pawlik TM
Eur J Cancer; 2021 May; 148():348-358. PubMed ID: 33774439
[TBL] [Abstract][Full Text] [Related]
38.
Wu J; Guo Y; Zuo ZF; Zhu ZW; Han L
World J Gastroenterol; 2023 May; 29(19):2961-2978. PubMed ID: 37274806
[TBL] [Abstract][Full Text] [Related]
39. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
[TBL] [Abstract][Full Text] [Related]
40. Cholangiocarcinoma.
Krasinskas AM
Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
